Summary
Updated Aug 30, 2026
Scott M. Plesha is CEO and President, Director of Pelthos Therapeutics Inc. (PTHS). 2 SEC Form 4 filings on record going back to 2025, most recently on 1 April 2026.
Recent Transactions
1Every recent SEC Form 4 transaction Scott M. Plesha has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Scott M. Plesha files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Todd C. Davis - $1000K of PTHS open-market activity in the last 12 months
- Ezra M. Friedberg - $314K of PTHS open-market activity in the last 12 months
- Knuettel Francis II - $40K of PTHS open-market activity in the last 12 months
- Peter Greenleaf - $37K of PTHS open-market activity in the last 12 months
- Matthew Pauls - $37K of PTHS open-market activity in the last 12 months
- Richard Malamut - $12K of PTHS open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Scott M. Plesha?
Scott M. Plesha is a corporate insider, tracked as CEO and President, Director of Pelthos Therapeutics Inc. (PTHS). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Scott M. Plesha last file a Form 4?
The most recent primary Form 4 on record is dated 1 April 2026, one of 2 filings going back to 2025.
Where can I see all of Scott M. Plesha's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Scott M. Plesha and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
